Novo Nordisk ADR(NVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 7:57 PM ET (Korea 10/24 08:57)
Full metrics table
| Index | - | P/E | 9.54 | EPS (ttm) | 4.09 | Insider Own | 0.01% | Shs Outstand | 3.35B | Perf Week | 0.57% |
| Market Cap | 130.66B | Forward P/E | 11.78 | EPS next Y | -0.92% | Insider Trans | - | Shs Float | 3.35B | Perf Month | 1.11% |
| Enterprise Value | 145.21B | PEG | - | EPS next Q | 0.73 | Inst Own | 9.8% | Short Float | 0.95% | Perf Quarter | -21.38% |
| Income | 18.19B | P/S | 2.54 | EPS this Y | -8.06% | Inst Trans | -0.06% | Short Ratio | 2.47 | Perf Half Y | -5.15% |
| Sales | 51.45B | P/B | 5.1 | EPS next 5Y | -0.48% | ROA | 21.81% | Short Interest | 31.62M | Perf YTD | -23.25% |
| Book/sh | 7.66 | P/C | 18.99 | EPS past 3/5Y | 26.28% 20.36% | ROE | 60.35% | 52W High | -39.14% ($64.16) | Perf Year | -26.64% |
| Cash/sh | 2.06 | P/FCF | 11.08 | Sales past 3/5Y | 23.19% 19.21% | ROIC | 34.67% | 52W Low | 11.19% ($35.12) | Perf 3Y | -59.79% |
| Dividend Est. | $1.76 (4.52%) | EV/EBITDA | 5.47 | EPS Y/Y TTM | 12.68% | Gross Margin | 80.65% | Volatility(W/M) | 1.32% 1.66% | Perf 5Y | -26.33% |
| Dividend TTM | 1.8 | EV/Sales | 2.82 | Sales Y/Y TTM | 13.21% | Oper. Margin | 45.38% | ATR (14) | 0.85 | Perf 10Y | 88.19% |
| Dividend Ex-Date | 2026/8/17 | Quick Ratio | 0.66 | EPS Q/Q | -18.69% | Profit Margin | 35.36% | RSI (14) | 45.64 | Recom | 3 |
| Dividend Gr. 3/5Y | 26.98% 19.93% | Current Ratio | 0.87 | Sales Q/Q | 4.59% | SMA20 | 1.7% ($38.4) | Beta | 0.72 | Target Price | $49.66 |
| Payout | 36.87% | Debt/Eq | 0.63 | Earnings | 2026/11/4 | SMA50 | -6.82% ($41.91) | Rel Volume | 0.72 | Prev Close | $39.43 |
| Employees | 68794 | LT Debt/Eq | 0.55 | EPS/Sales Surpr. | 24.09% 11.4% | SMA200 | -12.61% ($44.68) | Avg Volume(3M) | 12.81M | Price | $39.05 |
| IPO | 1981/4/30 | Option/Short | Yes/Yes | Trades | 39310 | Volume | 9,188,283 | Change | -0.96% |
A global leader in the diabetes and obesity treatment market, this pharmaceutical company was founded in Denmark in 1923 and is headquartered near Copenhagen. It holds a top global market share in insulin products and GLP-1-based obesity and diabetes treatments, with a core brand portfolio that includes Wegovy, Ozempic, and Rybelsus.
Over the past 1 year, on the lower side
39% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
Next earnings report: November 4
9 days to go.
NVO makes money but has a weak balance sheet
Of every $100 in sales, $45.38 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -8.1% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $547. Peers typically go for $1,463.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -26.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 4.52% annually in dividends.
Tap to view numbers
Institutions barely hold it
Institutions hold 9.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
NVOH Novo Nordisk A/S (B Shares) ADRhedged 0.97% 
EDEN iShares MSCI Denmark ETF 0.21% 
OZEM Roundhill GLP-1 & Weight Loss ETF 0.13% 
THNR Amplify Weight Loss Drug & Treatment ETF 0.12% 
HCOW Amplify COWS Covered Call ETF 0.12% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
NVOX Defiance Daily Target 2X Long NVO ETF 39M NVOH Novo Nordisk A/S (B Shares) ADRhedged 4M 
NVOC Corgi NVO 2x Daily ETF - It ranks #10 of 21 in the industry
Based on market cap of $131B.
PFE#9 Pfizer Inc $171B PER 39.8 
NVO#10 Novo Nordisk ADR $131B PER 9.5 
BMY#11 Bristol-Myers Squibb Co $126B PER 13.5 
GSK#12 GSK Plc ADR $102B PER 16.0 
SNY#13 Sanofi ADR $99B PER 21.4 
Earnings Analysis · 8/5 Novo Nordisk ($NVO) Q2 2026 Earnings Analysis — Adjusted Results and Guidance Raised, Modest After-Hours Rebound Investing Guides · 4/11 2026 U.S. High-Dividend Stock Guide — How to Screen Out the Traps Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is NVO?
NVO belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of NVO?
The market cap of NVO is approximately $130.7B, ranking 122 within its sector.
Does NVO pay dividends?
NVO has a dividend yield of approximately 4.52%, with an annual dividend of $1.76.
What is the P/E ratio of NVO?
NVO has a P/E ratio of approximately 9.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for NVO?
NVO has recorded a 52-week high of $64.16 and a low of $35.12.
